Our findings demonstrate that DOP1A, as well as the DOP1A-MON2-kinesin-1 complex, could be new candidates for neurodevelopmental disorders due to the potential effect on PLP1 and MAG, which are critical to myelination, but that needs more laboratory-validation of functional and genetic evidence. This evidence concerns the gene DOP1A and neurodevelopmental disorder.